Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Cash at End of Period

Last Annual Value

11.63M

3-Year CAGR

-7%

5-Year CAGR

31%

10-Year CAGR

14%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Cash at End of Period

ANEB · NASDAQ
CompanyCash at End of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
11.63M
1.1%-10.3%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
5.25M
-43.4%-36.4%N/A
93.93M
75.1%39.7%N/A
38.62M
7.9%-9.2%N/A
12.98M
-20.7%40.9%-10.3%
56.18M
-31.8%-17.4%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
3.04M
257.5%40.9%N/A
85.80M
31.4%-2.1%N/A
45.95M
71.8%-9.9%28.0%
6.21M
-33.1%-38.3%N/A
48.94M
-20.2%2.6%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72